At NetwoRx Bio, we decode and map the complex communication between immune, tumor, and stroma cells within the tumor microenvironment.
Using proprietary computational tools, we generate the ‘NetwoRx Map Score’ – a patient-specific metric that identifies the most relevant molecular interactions.
This score is designed to predict response to immunotherapeutic drugs (ICI), monoclonal antibodies and small molecule immune modulators – unlocking the next generation of immunotherapy.
Our Value Proposition
01 Optimal Clinical Trial Design
Matching single drugs or combinations of immunotherapeutic drugs to specific cancer indications and patients
02 Precision Medicine
Personalizing treatment strategies for an individual patient
The Need
Limited understanding of tumor-stroma-immune interactions
within the tumor microenvironment leads to:
20% - 30% 20% - 30% Patient Response Rates
$100,000+ per single treatment
Non-responders face delayed alternative treatments and frequently suffer immune adverse effects
The strongest predictive biomarker has only about 60% accuracy
>90% Failure Rate in Solid Cancer Clinical Trials
Thousands of running trials annually cost billions, yet only ~1/30 reaches clinical approval clinical approval
Out of 300 potential targets, most drug candidates remain untested across the majority of cancers
We Uniquely Explore the Immuno-Tumor Interactions
01
We integrate unique data of over 30 immune subsets, stroma, and tumor cells – an exceptionally reproducible data, including cell frequencies and deep transcriptomes of all physically sorted immune, tumor and stroma cells
02
We employ unique computational tools to map and score communication networks formed between these cells
03
We generate “NetwoRx Map Score’ per each molecular interaction (e.g. the PD1-PDL1) per each patient which provides unprecedented depth into understanding the immune communication within tumors
04
Initial data show a strong correlation between the ‘NetwoRx Map Score’ and ICI drug effectiveness, suggesting it can predict responses to specific drugs and combinations — both for individual patients and cancer types
Initial clinical data suggest that NetwoRx Bio Map Scores can predict individual patients' clinical benefit from IO or biological therapy in a cancer agnostic manner
Our Work in Progress
We already have highly detailed and comprehensive data for Renal and Bladder cancers, and we are in process of establishing the same for Liver, Lung, Colon, Brain, and Gastric cancers
Join us to increase the probability of your clinical trial success
Developing a drug?
We offer to use our system to help identifying effective drug combinations aiming to enhance patient outcomes
Looking for an additional cancer indication?
We offer to predict patients’ response rates, ahead of a clinical trial, to expand your drug’s potential
Leading Team
Ori Choshen CEO, Co-founder, Board member
CEO of VLX Ventures, founded 10+ biotech and computational biology startups.
DR. Ilan Volovitz, PH.D. Co-founder, Chief Scientific Officer
Head of the Cancer Immunotherapy lab The Neurosurgery dep.
Tel-Aviv Sourasky MC
DR. Ravit Geva, M.D. Co-founder, Chief Medical Officer
Head of the oncology clinical research unit, Deputy director – Oncology division
Tel-Aviv Sourasky MC
DR. Efrat Elis, PH.D. Head of Computation
Kelly Lipczyc Head of Lab
Board Members
Ori Choshen CEO, Co-founder, Board member
DR. Anat Cohen-Dayag, PH.D. Compugen President & CEO (NASDQ: CGEN)
